BioDuro Announces New Leadership Positions for Continued Expansion

–Key Hires to Support Scientific Excellence, Operational and Financial
Growth Plans and Global Business Development–

SAN DIEGO–(BUSINESS WIRE)–BioDuro, LLC, a leading drug discovery and development services
organization, announced today the appointment of four senior leadership
positions, including David Hedden, Ph.D. (Chief Scientific Officer),
Brett Truitt, MS, MBA (Vice President, cGMP Operations), Mohan
Thiruvazhi, Ph.D. (Vice President, Business Development), and Raymond
Li, CPA, MBA (Vice President, Finance).

“I am truly excited to be part of this exceptional team,” said Cyrus K.
Mirsaidi, President and CEO of BioDuro, LLC. “These key additions to the
leadership team, augmented by proven track record of our existing
executives, supremely positions BioDuro to continue the remarkable
growth we have realized over the past 3 years and to fulfill our
expectations for our next growth phase, with focus on innovation,
quality, and service to our clients, worldwide.”

David Hedden, Ph.D. promoted to Chief Scientific Officer

David will be responsible for the scientific leadership and management
of the Formulation and Analytical Development teams as well as provide
business development technical support. David brings 32 years of
pharmaceutical industry experience, most notably with Pfizer, UPM,
Ironwood, Searle/Pharmacia, Sandoz, Dupont, and Adagio, with expertise
in pharmaceutics, formulation, process development, and manufacturing
for small molecules.

“Since joining BioDuro, it has been exciting to participate in our
company’s commitment to quality science,” said Hedden. “I look forward
to leading my colleagues in this new position as we continue to innovate
in our CDMO operations, and help get much needed medicines to waiting
patients.”

Brett Truitt, MS, MBA appointed to Vice President, cGMP Operations

Brett will provide technical and business leadership for BioDuro’s cGMP
operations in its next phase of growth. He has 20 years of experience in
diverse pharmaceutical environments from early stage companies to
industry leading organizations most notably Flatley Discovery Labs,
Shire, Pfizer, and Proctor and Gamble. Most recently, he served as
Director of Pharmaceutics and Process Technology at Patheon in
Cincinnati.

“I am excited to work with BioDuro for the second time in my career –
the first as a client responsible for outsourcing to BioDuro an early
phase development and manufacturing project of a poorly-soluble drug,
and now as a member of the internal team,” said Truitt. “I look forward
to supporting BioDuro’s growth in this exciting new phase of the
company’s history and providing the same level of outstanding customer
service as I experienced as a client.”

Mohan Thiruvazhi, Ph.D. appointed to Vice President, Business
Development

Mohan brings to BioDuro a blend of scientific and commercial experience
from leading pharma and contract research organizations. He will be
responsible for global Business Development efforts in North America,
South America, and Europe. Mohan spent a decade at GVK BIO and Syngene
International, where he successfully executed US and European strategies
to expand geography and client footprints. Prior to that, he ran
chemistry operations for six years at ChemBridge Research Labs.

“I look forward to contributing to BioDuro’s growth as a premier
provider of integrated drug discovery, development, and manufacturing
services, through solution-based business development, at a time when it
has entered into a financial and strategic partnership with one of the
largest and most experienced global private equity investors committed
to building value for clients,” said Thiruvazhi.

Raymond Li, CPA, MBA, appointed to Vice President, Finance

Raymond brings a wealth of finance and accounting experience to BioDuro,
having served in senior positions at publicly traded, fortune 500
companies (K2 and Emerson Electric), augmented by his experience with
having completed IPO preparation for biopharma companies. In his last
position as VP of Finance and Operations for Ambrx, Raymond managed all
financial reporting to GAAP and IFRS standards and operationally managed
full implementation of a global ERP system. Raymond received his
master’s in accounting degree from University of Illinois, MBA from
Fudan University, and is a licensed and certified CPA in both California
and China.

“I am honored to join the BioDuro team at this exciting time and I am
delighted for the opportunity to help the organization achieve greater
financial results,” said Li. “I look forward to building the core
financial platforms for BioDuro’s significant further growth.”

About BioDuro

BioDuro is a leading global life sciences contract research, development
and manufacturing organization that provides biopharmaceutical clients
and partners with comprehensive, fully integrated drug discovery
services spanning target identification to IND filing, through to cGMP
manufacture of drug product for clinical trials. With depth and breadth
of therapeutic expertise in small and large molecule discovery,
development and scale up, combined with unique technology platforms such
as high content 3D drug screening, in-vivo translational models, and
bioavailability enhancement of insoluble compounds, BioDuro is well
positioned to help biopharmaceutical partners significantly accelerate
their lead discovery programs, and de-risk development programs for
higher value outcomes. Visit www.bioduro.com.

Contacts

Julie Silverio
Sales & Marketing Support Specialist
[email protected]